TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...

"TNKase provides a faster and simpler administration, which can be critical for anyone who is dealing with an acute stroke." Approval of TNKase was granted to Genentech.

This approval of TNKase marks Genentech’s second approval for stroke, reinforcing the company's long-standing dedication to advancing stroke care as the developer of the only two FDA-approved ...